Pramlintide improved glycaemic control and reduced weight in patients with type 2 diabetes treating to target with basal insulin

被引：0
|
作者：
Wilhelm, K. [1 ]
Riddle, M. [2 ]
Zhang, B. [1 ]
Maier, H. [1 ]
Kolterman, O. [1 ]
机构：
[1] Amylin Pharmaceut, San Diego, CA USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1011
引用
收藏
页码：S409 / S409
页数：1
相关论文
共 50 条
  • [21] Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA
    Mauricio, Didac
    Meneghini, Luigi
    Seufert, Jochen
    Liao, Laura
    Wang, Hongwei
    Tong, Liyue
    Cali, Anna
    Stella, Peter
    Carita, Paulo
    Khunti, Kamlesh
    DIABETES OBESITY & METABOLISM, 2017, 19 (08): : 1155 - 1164
  • [22] Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?
    Watson, L.
    Wilson, B. P.
    Alsop, J.
    Kumar, S.
    DIABETES OBESITY & METABOLISM, 2011, 13 (09): : 823 - 831
  • [23] Achieving postprandial glucose control with lixisenatide improves glycaemic control in patients with type 2 diabetes mellitus on basal insulin
    Paranjape, S.
    Stager, W.
    Berria, R.
    Leiter, L. A.
    DIABETOLOGIA, 2015, 58 : S383 - S383
  • [24] Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 2 diabetes during treatment for 52 weeks
    Fineman, M
    Gottlieb, A
    Skare, S
    Kolterman, O
    DIABETES, 2000, 49 : A106 - A106
  • [25] Vildagliptin added to basal insulin glargine improves glycaemic control and reduces glycaemic excursions in type 2 diabetes
    Brooks, J.
    Bravis, V.
    Morgenstern, S.
    Hui, E.
    Gohel, B.
    Savarananthan, T.
    Carrolls, M.
    Devendra, D.
    DIABETOLOGIA, 2009, 52 : S294 - S295
  • [26] A Smartphone for adjustment of basal insulin dose and for coaching: benefits in terms of glycaemic control for type 2 diabetes patients
    Daoudi, A.
    Joubert, M.
    Franc, S.
    Fagour, C.
    Benhamou, P-Y
    Reznik, Y.
    Rodier, M.
    Boucherie, B.
    Benamo, E.
    Schaepelynck, P.
    Guerci, B.
    Dardari, D.
    Penfornis, A.
    Charpentier, G.
    DIABETOLOGIA, 2013, 56 : S426 - S426
  • [27] Effect of pramlintide treatment on markers of cardiovascular risk in patients with type 2 diabetes using basal insulin
    Lush, C.
    Zhang, B.
    Maggs, D.
    Darsow, T.
    Kolterman, O.
    DIABETOLOGIA, 2007, 50 : S514 - S514
  • [28] Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
    Kothny, W.
    Foley, J.
    Kozlovski, P.
    Shao, Q.
    Gallwitz, B.
    Lukashevich, V.
    DIABETES OBESITY & METABOLISM, 2013, 15 (03): : 252 - 257
  • [29] Glycaemic control with insulin glulisine versus regular human insulin in a basal-bolus regimen in patients with Type 2 diabetes
    Dailey, G
    Rosenstock, J
    Moses, R
    Ways, K
    DIABETOLOGIA, 2004, 47 : A265 - A266
  • [30] Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
    Hollander, P
    Maggs, DG
    Ruggles, JA
    Fineman, M
    Shen, L
    Kolterman, OG
    Weyer, C
    OBESITY RESEARCH, 2004, 12 (04): : 661 - 668
12345